One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis. (PubMed, Target Oncol) - Sep 16, 2026 - "One-week inflammatory kinetics provided early prognostic information before first scheduled imaging in first-line nivolumab plus ipilimumab-treated metastatic renal cell carcinoma. A simple direction-of-change rule for pan-immune-inflammation value may complement baseline risk assessment; however, prospective external validation is required before clinical implementation."
Journal • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Haruka Miyata; Hirohito Naito; Hiroshi Kikuchi; Kazuyuki Numakura; Kojiro Ohba; Kosuke Ueda; Masaharu Oki; Mikio Sugimoto; Norihiko Tsuchiya; Sei Naito; Shin Kobayashi; Shintaro Narita; Takahiro Osawa; Takuma Ishihara; Toru Inoue; Toshitaka Shin; Tsukasa Igawa; Yuya Sekine
|